home / stock / cycc / cycc news

CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 11/13/19

Stock Information
Company Name: Cyclacel Pharmaceuticals Inc.
Stock Symbol: CYCC
Market: NASDAQ
Website: cyclacel.com
Menu
CYCC CYCC Quote CYCC Short CYCC News CYCC Articles CYCC Message Board
Get CYCC Alerts

News, Short Squeeze, Breakout and More Instantly...
CYCC - Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results

– Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent – – Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, ...
CYCC - Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results on Wedn...

CYCC - Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting

BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced that data from Cyclacel’s CYC065 and sapa...

CYCC - Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at th...
CYCC - Cyclacel Pharmaceuticals (CYCC) Investor Presentation - Slideshow

The following slide deck was published by Cyclacel Pharmaceuticals, Inc. in conjunction with this Read more ...

CYCC - Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors

BERKELEY HEIGHTS, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced treatment of the first patient with an oral for...

CYCC - Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

BERKELEY HEIGHTS, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at th...
CYCC - Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2019 Results - Earnings Call Transcript

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2019 Results Earnings Conference Call August 13, 2019, 04:30 PM ET Company Participants Paul McBarron - Executive VP of Finance, CFO, COO, Secretary & Executive Director Spiro Rombotis - President, CEO & Executive Director Alexande...

CYCC - Cyclacel Pharmaceuticals EPS in-line

Cyclacel Pharmaceuticals (NASDAQ: CYCC ): Q2 GAAP EPS of -$0.16 in-line. Cash and cash equivalents of $17.5M Press Release More news on: Cyclacel Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

CYCC - Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results

- Conference Call Scheduled August 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based o...
Previous 10 Next 10